Downloads
Abstract
Objective: This study aimed to compare the efficacy of dapagliflozin and empagliflozin as add-on therapies for type 2 diabetes mellitus (T2DM) over 6 months in a real-world setting, focusing on key metabolic parameters.
Methods: We conducted a single-center, retrospective observational study involving 74 T2DM patients receiving either dapagliflozin (10mg) or empagliflozin (25mg) as add-on therapy. Data from 843 patients’s electronic medical records were collected at the Center for Endocrinology and Diabetes, Da Nang Family Hospital, between May 2021 and June 2023. Baseline data and data from the 3rd and 6th months of treatment were analyzed using SPSS software (version 20.0). Statistical significance was set at p < 0.05.
Results: The mean participant age was 58.8 years, with 54.1% females. Mean baseline HbA1c and fasting blood glucose were 8.18% and 9.1 mmol/L, respectively. After 6 months of SGLT2i treatment, both medications significantly improved glycemic control: HbA1c decreased from 8.18% to 7.3% (p < 0.05), and fasting plasma glucose dropped from 9.1 mmol/L to 7.4 mmol/L (p < 0.05). Systolic blood pressure also decreased significantly, from 130.7 mmHg to 126.5 mmHg (p < 0.05). Although a trend towards weight reduction (1.5 kg) was observed, it was not statistically significant (p > 0.05). Notably, empagliflozin led to a significantly greater decrease in fasting plasma glucose compared to dapagliflozin (p < 0.05). No other significant differences in metabolic parameters were observed between the groups at either 3 or 6 months.
Conclusion: Both dapagliflozin and empagliflozin demonstrated significant efficacy as add-on therapies forT2DM patients, improving glycemic control, reducing blood pressure, and potentially promoting weight loss. While empagliflozin showed slightly better BMI, body weight and fasting plasma glucose reduction after 3 months, further research is needed to confirm this finding and explore underlying mechanisms.
References
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice. 2019;157:107843.
The top 10 causes of death: World Health Organization; 2017 [updated January 2017; cited 2017 February 9, 2017].
Sheng Z, Cao J-Y, Pang Y-C, Xu H-C, Chen J-W, Yuan J-H, et al. Effects of lifestyle modification and anti-diabetic medicine on prediabetes progress: a systematic review and meta-analysis. Frontiers in endocrinology. 2019;10:455.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Supplement_1):S140-S157.
Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical Endocrinology consensus statement: comprehensive Type 2 diabetes management algorithm–2023 update. Endocrine Practice. 2023;29(5):305-340.
Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocrine Practice. 2008;14(6):782-790.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2019;380(4):347-357.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015;373(22):2117-2128.
Committee ADAPP. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care.2023;47(Supplement_1):S20-S42.
Mosenzon O, Raz I, Wiviott SD, Schechter M, Goodrich EL, Yanuv I, et al. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes care. 2022;45(10):2350-2359.
Jorsal A, Persson F, Bruun JM. Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. European Heart Journal. 2020;41(2):328-328.
Shin H, Schneeweiss S, Glynn RJ, Patorno E. Trends in first-line glucose-lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA. Diabetes Care. 2021;44(8):1774-1782.
Ton TT, Tran ATN, Do IT, Nguyen H, Nguyen TTB, NguyenMT, et al. Trends in prediabetes and diabetes prevalence and associated risk factors in Vietnamese adults. Epidemiol Health. 2020;42(0):e2020029-0.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes—2023. Diabetes care. 2023;46(Supplement_1):S19-S40.
Navaneethan SD, Zoungas S, Caramori ML, Chan JC, Heerspink HJ, Hurst C, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Annals of internal medicine. 2023;176(3):381-387.
Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015;38(3):365-72.
Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebocontrolled trial. Diabetes, Obesity and Metabolism. 2014;16(2):147-158.
Cai X, Yang W, Gao X, Chen Y, Zhou L, Zhang S, et al. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A MetaAnalysis. Obesity (Silver Spring). 2018;26(1):70-80.
Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell metabolism. 2017;26(1):27-38.
Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes research and clinical practice. 2004;65:S23-S27.
Russell - Jones D, Khan R. Insulin - associated weight gain in diabetes - causes, effects and coping strategies. Diabetes, Obesity and Metabolism. 2007;9(6):799-812.
Brown A, Guess N, Dornhorst A, Taheri S, Frost G. Insulin - associated weight gain in obese type 2 diabetes mellitus patients: What can be done? Diabetes, Obesity and Metabolism. 2017;19(12):1655-1668.
Ku EJ, Lee DH, Jeon HJ, Oh TK. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study. Diabetes Res Clin Pract. 2019;151:65-73.
Cha SA, Park YM, Yun JS, Lim TS, Song KH, Yoo KD, et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis. 2017;16(1):58.
Calapkulu M, Cander S, Gul OO, Ersoy C. Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(2):1031-1034.
| Published | 30-11-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 8 (2024) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.16.8.12 | |
| Keywords | Type 2 Diabetes, SGLT2i, metabolic parameters, empagliflozin, dapagliflozin |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Journal of Clinical Medicine Hue Central Hospital